Download PDF

1. Company Snapshot

1.a. Company Description

Orchestra BioMed Holdings, Inc.operates as a biomedical innovation company.The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.


Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions.The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease.Orchestra BioMed Holdings, Inc.


is based in New Hope, Pennsylvania.

Show Full description

1.b. Last Insights on OBIO

The recent 3-month performance of Orchestra BioMed Holdings, Inc. was negatively impacted by a loss of $0.49 per share in Q1 2025, exceeding the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $0.38 per share in the same period last year. The company's financial results were also affected by escalating medical care costs, partly offset by growing membership in its government-backed Medicaid insurance plans.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov -26

Source: globenewswire.com

Card image cap

Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

Nov -11

Source: globenewswire.com

Card image cap

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Beats Revenue Estimates

Nov -11

Source: zacks.com

Card image cap

Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

Nov -10

Source: globenewswire.com

Card image cap

Orchestra BioMed to Host Business Update Call on November 12, 2025

Nov -03

Source: globenewswire.com

Card image cap

Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements

Oct -28

Source: globenewswire.com

Card image cap

Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial

Oct -27

Source: globenewswire.com

Card image cap

Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit

Oct -09

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.37%)

6. Segments

Medical Device

Expected Growth: 8.37%

Orchestra BioMed Holdings, Inc.'s Medical Device segment growth of 8.37% is driven by increasing demand for minimally invasive treatments, advancements in cardiovascular and orthopedic technologies, and strategic partnerships expanding product offerings and geographic reach.

7. Detailed Products

BackBeat Cardiac Neuromodulation Therapy

A minimally invasive, implantable device that utilizes cardiac neuromodulation therapy to treat hypertension and heart failure

Moderato Initial Success Optimization System

A software-based system that optimizes the programming of cardiac rhythm management devices, such as pacemakers and implantable cardioverter-defibrillators

Virtue Signal Processing System

A signal processing technology that enhances the detection and analysis of cardiac signals, enabling more accurate diagnosis and treatment of cardiac arrhythmias

8. Orchestra BioMed Holdings, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Orchestra BioMed Holdings, Inc. is medium due to the presence of alternative treatments and products in the medical device industry.

Bargaining Power Of Customers

The bargaining power of customers for Orchestra BioMed Holdings, Inc. is low due to the specialized nature of its products and the lack of price sensitivity among its customer base.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Orchestra BioMed Holdings, Inc. is medium due to the presence of multiple suppliers in the market and the company's moderate dependence on them.

Threat Of New Entrants

The threat of new entrants for Orchestra BioMed Holdings, Inc. is high due to the growing demand for medical devices and the relatively low barriers to entry in the industry.

Intensity Of Rivalry

The intensity of rivalry for Orchestra BioMed Holdings, Inc. is high due to the presence of established competitors and the high stakes in the medical device industry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 2.42%
Debt Cost 3.95%
Equity Weight 97.58%
Equity Cost 5.03%
WACC 5.01%
Leverage 2.48%

11. Quality Control: Orchestra BioMed Holdings, Inc. passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Cara Therapeutics

A-Score: 4.1/10

Value: 7.4

Growth: 1.1

Quality: 5.4

Yield: 0.0

Momentum: 10.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Ikena Oncology

A-Score: 3.3/10

Value: 6.4

Growth: 1.8

Quality: 5.8

Yield: 0.0

Momentum: 2.0

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
HCW Biologics

A-Score: 2.8/10

Value: 8.0

Growth: 4.1

Quality: 4.9

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Sangamo Therapeutics

A-Score: 2.8/10

Value: 7.2

Growth: 3.3

Quality: 4.1

Yield: 0.0

Momentum: 2.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Eyenovia

A-Score: 2.6/10

Value: 7.6

Growth: 4.8

Quality: 3.3

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Orchestra BioMed

A-Score: 2.2/10

Value: 6.0

Growth: 2.9

Quality: 3.6

Yield: 0.0

Momentum: 0.0

Volatility: 0.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

4.46$

Current Price

4.46$

Potential

-0.00%

Expected Cash-Flows